← Back to headlines
Eli Lilly Price Target Raised After FDA Approval for Fundayo
Eli Lilly and Company (LLY) saw its price target raised by analysts following the FDA's approval of its new drug, Fundayo.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Nvidia Backs OpenAI's Ohio Data Center Project with $105 Billion Guarantee
7m ago
Einride to Deploy 500 Tesla Electric Trucks for North American Fleet
21m ago
China's Top Envoy to Visit Seoul Amid Shifting US-South Korea Ties
31m ago
Low Danube Water Levels Threaten Paks Nuclear Power Plant Operations
37m ago